Risk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination: A systematic review and meta-analysis.

Autor: Steinberg J; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Hughes S; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Hui H; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Allsop MJ; Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Egger S; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., David M; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.; School of Medicine and Dentistry, Griffith University, Gold Coast, Australia., Caruana M; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Coxeter P; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Carle C; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Onyeka T; Department of Anaesthesia/Pain & Palliative Care Unit, College of Medicine, University of Nigeria, Ituku-Ozalla Campus, Enugu, Nigeria.; IVAN Research Institute, Enugu, Nigeria., Rewais I; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Monroy Iglesias MJ; Translational Oncology and Urology Research (TOUR), Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Vives N; Cancer Screening Unit, Institut Català d'Oncologia (ICO), Early Detection of Cancer Group, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.; Ciber Salud Pública (CIBERESP), Instituto Salud Carlos III, Madrid, Spain., Wei F; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer, Lyon, France., Abila DB; Makerere University College of Health Sciences, Kampala, Uganda., Carreras G; Oncologic Network, Prevention and Research Institute (ISPRO), Florence, Italy., Santero M; Iberoamerican Cochrane Centre, IIB Sant Pau-Servei d'Epidemiologia Clínica i Salut Pública, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., O'Dowd EL; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK., Lui G; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Tolani MA; Department of Surgery, Ahmadu Bello University, Zaria, Nigeria., Mullooly M; School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland., Lee SF; Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore.; Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hospital Authority, Hong Kong, China., Landy R; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA., Hanley SJB; Department of Academic Primary Care, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland.; Center for Environmental and Health Sciences, Hokkaido University, Sapporo, Japan., Binefa G; Cancer Screening Unit, Cancer Prevention and Control Program, Catalan Institute of Oncology, Hospitalet de Llobregat, Barcelona, Spain.; Early Detection of Cancer Research Group, EPIBELL Programme, Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Barcelona, Spain., McShane CM; Centre for Public Health, Queen's University Belfast, Institute of Clinical Sciences Block B, Royal Victoria Hospital, Belfast, Northern Ireland., Gizaw M; Department of Preventive Medicine, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.; Institute for Medical Epidemiology, Biometrics and Informatics, Martin Luther University of Halle-Wittenberg, Halle, Germany.; NCD Working Group, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia., Selvamuthu P; Chennai Antiviral Research and Treatment Center and Clinical Research Site (CART CRS), Infectious Diseases Medical Center, Voluntary Health Services, Chennai, India., Boukheris H; University Abderrahmane Mira of Bejaia, School of Medicine, Bejaia, Algeria.; Department of Epidemiology and Preventive Medicine, University Hospital of Bejaia, Bejaia, Algeria., Nakaganda A; Department of Cancer Epidemiology and Clinical Trials, Uganda Cancer Institute, Kampala, Uganda., Ergin I; Department of Public Health, Faculty of Medicine, Ege University, Bornova, Turkey., Moraes FY; Department of Oncology, Queen's University, Kingston, Ontario, Canada., Timilshina N; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada., Kumar A; Department of Anatomy, All India Institute of Medical Sciences-Patna, Patna, India., Vale DB; Department of Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas, Brazil., Molina-Barceló A; Cancer and Public Health Research Unit, Biomedical Research Foundation FISABIO, Valencia, Spain., Force LM; Department of Health Metrics Sciences, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA.; Department of Pediatrics, Division of Hematology/Oncology, University of Washington, Seattle, Washington, USA., Campbell DJ; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Wang Y; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Wan F; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Baker AL; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Singh R; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Salam RA; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia., Yuill S; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.; School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Shah R; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France., Lansdorp-Vogelaar I; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands., Yusuf A; Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore & Peshawar, Lahore, Pakistan., Aggarwal A; Department of Health Services Research and Policy, School of Hygiene and Tropical Medicine, King's College London, London, UK.; Department of Oncology, Guy's & St Thomas NHS Trust, London, UK., Murillo R; Centro Javeriano De Oncologia - Hospital Universitario San Ignacio, Bogotá, Colombia.; Pontificia Universidad Javeriana, Bogotá, Colombia., Torode JS; Institute of Cancer Policy, King's College London, London, UK.; Research Oncology, Bermondsey Wing, Guy's Hospital, London, UK., Kliewer EV; Department of Cancer Control Research, BC Cancer Research Institute, Vancouver, British Columbia, Canada., Bray F; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France., Chan KKW; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Canadian Centre for Applied Research in Cancer Control, Vancouver, British Columbia, Canada., Peacock S; Department of Cancer Control Research, BC Cancer Research Institute, Vancouver, British Columbia, Canada.; Canadian Centre for Applied Research in Cancer Control, Vancouver, British Columbia, Canada.; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada., Hanna TP; Division of Cancer Care and Epidemiology, Cancer Research Institute at Queen's University, Kingston, Ontario, Canada.; Department of Oncology and Department of Public Health Sciences, Queen's University, Kingston, Ontario, Canada., Ginsburg O; Center for Global Health, National Cancer Institute, Rockville, Maryland, USA., Van Hemelrijck M; Translational Oncology and Urology Research (TOUR), Centre for Cancer, Society, and Public Health, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Sullivan R; Institute of Cancer Policy, King's College London, London, UK., Roitberg F; Department of Non-Communicable Diseases, World Health Organisation, Geneva, Switzerland.; Hospital Sírio Libanês, São Paulo, Brazil.; Rede Ebserh, Rede Brasileira de Serviços Hospitalares, Brasília, Brazil., Ilbawi AM; Hospital Sírio Libanês, São Paulo, Brazil., Soerjomataram I; Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France., Canfell K; The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2024 Apr 15; Vol. 154 (8), pp. 1394-1412. Date of Electronic Publication: 2023 Dec 11.
DOI: 10.1002/ijc.34798
Abstrakt: While previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I 2  = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I 2  = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I 2  = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I 2  = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.
(© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
Databáze: MEDLINE
Externí odkaz: